# Hematopathology * **Definition:** The study of blood diseases, including the diagnosis and characterization of hematologic disorders through examination of blood, bone marrow, and lymphatic tissues. * **Taxonomy:** Specialties / Hematopathology ## News * Selected news on the topic of **Hematopathology**, for healthcare technology leaders * 1.8K news items are in the system for this topic * Posts have been filtered for tech-related keywords | Date | Title | Source | | --- | --- | --- | | 5/27/2025 | [**The specialty that feels most valued by employers**](https://www.beckershospitalreview.com/quality/hospital-physician-relationships/the-specialty-that-feels-most-valued-by-employers/) | [[Beckers Hospital Review]] | | 3/11/2025 | [**Pramana and ARUP Laboratories Partner to Digitize Pathology Slides and Develop AI-Powered Hematopathology Algorithms for Deployment via Edge AI**](https://uk.finance.yahoo.com/news/pramana-arup-laboratories-partner-digitize-121000642.html) | [[Yahoo Finance UK]] | | 3/10/2025 | [**Pramana and ARUP Laboratories Partner to Digitize Pathology Slides and Develop AI-Powered Hematopathology Algorithms for Deployment via Edge AI**](https://www.morningstar.com/news/business-wire/20250311204738/pramana-and-arup-laboratories-partner-to-digitize-pathology-slides-and-develop-ai-powered-hematopathology-algorithms-for-deployment-via-edge-ai) | [[Morningstar]] | | 2/28/2025 | [**Healthcare Moves: A Monthly Summary of Hires, Exits and Layoffs**](https://medcitynews.com/2025/02/healthcare-moves-layoffs-hires-executive/) | [[MedCity News]] | | 1/14/2025 | [**Ambience Healthcare and St. Luke's Health System Partner to Reduce Clinician Burnout ...**](https://finance.yahoo.com/news/ambience-healthcare-st-lukes-health-140300808.html) | [[Yahoo Finance]] | | 12/28/2024 | [**Artificial Intelligence - Healthcare IT News**](https://www.healthcareitnews.com/taxonomy/term/7341/m89gsv6dzcjz.jsp/page/2?type=video) | [[Healthcare IT News]] | | 12/26/2024 | [**Cosmos Health Appoints Dimitrios Trafalis as Head of Oncology - FirstWord Pharma**](https://firstwordpharma.com/story/5923956) | [[FirstWord PHARMA]] | | 12/20/2024 | [**Lessons in Value From Other Specialties**](https://www.ajmc.com/view/lessons-in-value-from-other-specialties) | [[AJMC]] | | 12/19/2024 | [**Has 2024 Been The Big Year For AI In Healthcare?**](https://www.forbes.com/councils/forbesbusinessdevelopmentcouncil/2024/12/20/has-2024-been-the-big-year-for-ai-in-healthcare/) | [[Forbes]] | | 12/17/2024 | [**Caris Life Sciences Appoints Dr. James Hamrick as Chairman of the Caris Precision ...**](https://www.prnewswire.com/news-releases/caris-life-sciences-appoints-dr-james-hamrick-as-chairman-of-the-caris-precision-oncology-alliance-302332807.html) | [[PR Newswire]] | | 12/11/2024 | [**Do AI Diagnostics have a role in telemedicine? What does this mean for healthcare equity?**](https://www.healthtechmagazines.com/do-ai-diagnostics-have-a-role-in-telemedicine-what-does-this-mean-for-healthcare-equity/) | [[Health Tech Magazines]] | | 12/5/2024 | [**ConcertAI and NeoGenomics Announce New AI Software-as-a-Service Solution for ... - Morningstar**](https://www.morningstar.com/news/business-wire/20241205002549/concertai-and-neogenomics-announce-new-ai-software-as-a-service-solution-for-hematology-clinical-research) | [[Morningstar]] | | 11/25/2024 | [**Revolutionizing Oncology and Mesothelioma Cancer: How Health IT is Transforming Diagnosis and Treatment**](https://www.healthitanswers.net/revolutionizing-oncology-and-mesothelioma-cancer-how-health-it-is-transforming-diagnosis-and-treatment/) | [[Health IT Answers]] | | 10/31/2024 | [**NCODA Fall Summit Recap: Key Sessions and Expert Interviews From the 2024 Meeting**](https://www.pharmacytimes.com/view/ncoda-fall-summit-recap-key-sessions-and-expert-interviews-from-the-2024-meeting) | [[Pharmacy Times]] | | 10/29/2024 | [**Asia-Pacific Digital Diagnostics Market Analysis and Forecast, 2023-2024 & 2033: Synergetic Partnership Opportunities with Hospitals and Diagnostic Centers Fuel Opportunities - ResearchAndMarkets.com**](http://www.businesswire.com/news/home/20241029232642/en/Asia-Pacific-Digital-Diagnostics-Market-Analysis-and-Forecast-2023-2024-2033-Synergetic-Partnership-Opportunities-with-Hospitals-and-Diagnostic-Centers-Fuel-Opportunities---ResearchAndMarkets.com/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 10/28/2024 | [**Blue Shield of California Appoints Dr. Deneen Vojta as Executive Vice President for Health Solutions**](https://www.prnewswire.com/news-releases/blue-shield-of-california-appoints-dr-deneen-vojta-as-executive-vice-president-for-health-solutions-302286371.html) | [[PR Newswire]] | | 10/16/2024 | [**AI in Healthcare: Transforming Diagnosis and Treatment**](https://healthcareguys.com/2024/10/16/ai-in-healthcare-transforming-diagnosis-and-treatment/?utm_source=rss&utm_medium=rss&utm_campaign=ai-in-healthcare-transforming-diagnosis-and-treatment) | [[The Healthcare Guys]] | | 10/7/2024 | [**Siloam Hospitals Group and Philips sign AI capability MoU to support Indonesia's ... - Morningstar**](https://www.morningstar.com/news/globe-newswire/1000995993/siloam-hospitals-group-and-philips-sign-ai-capability-mou-to-support-indonesias-healthcare-transformation-strategy) | [[Morningstar]] | | 10/6/2024 | [**Metropolis Healthcare launches MiLES initiative to bridge the gap between academic learning and hands-on skills in the healthcare sector**](https://markets.businessinsider.com/news/stocks/metropolis-healthcare-launches-miles-initiative-to-bridge-the-gap-between-academic-learning-and-hands-on-skills-in-the-healthcare-sector-1033824596) | [[Business Insider Markets]] | | 9/2/2024 | [**Global Hematology Analyzers and Reagents Market to Hit $8 Billion by 2030: Technological Advances and Rising Blood Disorders Drive Growth**](http://prsync.com/market-study-report/global-hematology-analyzers-and-reagents-market-to-hit--billion-by--technological-advances-and-rising-blood-disorders-drive-grow-4264813/) | [[PRSync]] | | 8/8/2024 | [**Meiji Seika Pharma Opens New Office in Boston Area to Pursue Investment Opportunities in ...**](https://www.businesswire.com/news/home/20240808269845/en/Meiji-Seika-Pharma-Opens-New-Office-in-Boston-Area-to-Pursue-Investment-Opportunities-in-Innovative-Drugs-and-Technologies) | [[Business Wire]] | | 8/8/2024 | [**Meiji Seika Pharma Opens New Office in Boston Area to Pursue Investment Opportunities in Innovative Drugs and Technologies**](http://www.businesswire.com/news/home/20240808269845/en/Meiji-Seika-Pharma-Opens-New-Office-in-Boston-Area-to-Pursue-Investment-Opportunities-in-Innovative-Drugs-and-Technologies/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 8/5/2024 | [**Renowned surgical oncologist takes leadership role at NYU Grossman Long Island School of Medicine**](https://www.news-medical.net/news/20240805/Renowned-surgical-oncologist-takes-leadership-role-at-NYU-Grossman-Long-Island-School-of-Medicine.aspx) | [[News Medical Net]] | | 7/22/2024 | [**CAR T-cell Therapy Market worth $29.0 billion by 2029 driven by Rising ... - PR Newswire**](https://www.prnewswire.com/news-releases/car-t-cell-therapy-market-worth-29-0-billion-by-2029-driven-by-rising-technological-advancements--marketsandmarkets-302202428.html) | [[PR Newswire]] | | 7/17/2024 | [**Vaniam Group™ Welcomes Christa Gott as Senior Vice President of Business Strategy**](https://www.prnewswire.com/news-releases/vaniam-group-welcomes-christa-gott-as-senior-vice-president-of-business-strategy-302199534.html) | [[PR Newswire]] | ## Specialty Overview (Some LLM-derived content — please confirm with above primary sources) ### Key Players - **Hematology/Oncology Pharmacy Association (HOPA)**: An organization supporting pharmacy professionals in hematology and oncology. - **Agios Pharmaceuticals**: A leader in developing therapies for rare hematologic diseases, including PK deficiency. - **Dr. Elvin Wagenblast**: A researcher utilizing advanced genetic tools to study the transition of blood cells from normal function to leukemia. - **TC BioPharm**: A biopharmaceutical company specializing in cell therapy, particularly for blood cancers like Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). - **Adaptive Biotechnologies**: A biotechnology company specializing in immune-driven medicine, particularly in hematology. - **Beckman Coulter Diagnostics**: A leading company in laboratory diagnostics, focusing on hematology and urinalysis, committed to advancing healthcare through innovative testing solutions. - **Versant Diagnostics**: A pathology provider aiming to improve patient outcomes through innovative solutions in anatomic pathology. - **DelveInsight**: A company that provides KOL profiling support to enhance strategic engagement with Key Opinion Leaders in hematology. - **Sysmex America, Inc.**: A company known for its innovative diagnostic products, particularly in hematology and oncology. - **Dr. Daniel Pollyea**: A researcher concentrating on leukemia stem cells to develop targeted treatments. - **Professor Trafalis**: A distinguished academic in pharmacology and clinical pharmacology specializing in oncology-hematology and personalized cancer therapies. - **Octapharma**: A leading privately owned company specializing in hematology, immunotherapy, and critical care, providing life-saving therapies globally. - **ConcertAI**: A healthcare technology company focused on enhancing research analytics and clinical trial design in hematological malignancies. - **Dr. Joanna Melo-Cardenas**: A researcher focusing on inflammation in blood cells. - **CareDx, Inc.**: A biotechnology company focused on developing solutions for transplant patients, including the AlloCell test for monitoring cell therapy in hematologic cancers. - **Dr. Vijay G. Sankaran**: A clinician-scientist recognized for his contributions to blood cell development and gene therapy for sickle cell disease. - **NeoGenomics**: A company partnering with ConcertAI to enhance clinical trial design and research analytics for hematological malignancies. - **Guardant Health, Inc.**: A precision oncology company specializing in advanced blood and tissue tests for cancer diagnostics. - **MaaT Pharma**: A biotechnology company specializing in microbiome ecosystem therapies for cancer patients, with a focus on hematology. ### Partnerships and Collaborations - **Leukemia & Lymphoma Society (LLS)**: Supports research efforts and recognizes significant contributions to blood cancer research and patient care. - **ConcertAI and NeoGenomics**: Collaborating on CTO-H, a software-as-a-service solution for enhancing research analytics and clinical trial design for hematological malignancies. - **CareDx and TC BioPharm**: Partnering to conduct pharmacokinetic analysis in the ACHIEVE clinical trial for cell therapy in blood cancers. - **Versant Diagnostics and Avero Diagnostics**: Affiliation to enhance pathology practices and improve patient outcomes. - **Clario and PathAI**: Partnering to enhance drug development for inflammatory bowel disease through advanced digital pathology and endoscopy solutions. - **Lowcountry Oncology Associates and OneOncology**: Partnering to improve cancer service delivery in Charleston, South Carolina, expanding services across new clinics. - **Providence, Microsoft, and the University of Washington**: Developed an AI-powered pathology model named Prov-GigaPath for medical use. - **Caris Precision Oncology Alliance**: A global network of 96 member institutions, including 47 NCI-designated comprehensive cancer centers, aimed at improving clinical outcomes for cancer patients through collaboration. - **Cosmos Health and Professor Trafalis**: Collaboration to lead research initiatives aimed at developing innovative cancer treatment strategies. - **Sapio Sciences and CREO**: Strategic partnership to enhance laboratory management and facilitate digital transformation in life science research. - **Paige and UK Hospital Systems**: Evaluating Paige's AI technology for diagnosing prostate cancer in clinical settings. - **Ichnos Glenmark Innovation**: A collaboration focused on accelerating drug discovery in cancer treatment. - **Octapharma and Kinaxis**: Partnered to enhance supply chain management through data system integration, improving agility and decision-making. - **ION and cCARE**: These organizations have collaborated to enhance cancer care services in the San Diego and Murrieta communities. - **Royal Philips and Siloam Hospitals Group**: A partnership to enhance AI capabilities in Indonesia's healthcare sector. - **Silence Therapeutics**: Partners with AstraZeneca and Hansoh Pharma to advance its precision-engineered medicines. - **Truveta**: Collaborates with over 100 organizations to utilize its extensive healthcare data for research and AI model training. - **ZayaAI and Enjinstarter**: Strategic partnership to leverage AI and blockchain technology for improving healthcare diagnostics and outcomes. ### Innovations, Trends, and Initiatives - **AI in Hematopathology**: Artificial intelligence is transforming blood test analysis by improving precision, reducing human error, and accelerating result processing. - **HNL Lab Medicine**: Integrating advanced digital pathology services to enhance diagnostic precision and patient care. - **Hematology Analyzers Market**: Forecasted to reach USD 8 billion by 2030, driven by technological advancements and the rising prevalence of blood disorders. - **AI Integration in Hematology**: The integration of automation and AI in hematology analyzers is enhancing diagnostic accuracy and efficiency. - **Rare Hematology Market Growth**: Significant growth driven by FDA approvals enhancing treatment options for conditions like hemophilia and sickle cell disease. - **Digital Pathology Assistant toolkit**: Aims to simplify the processing and analysis of pathology imaging data. - **CRISPR Technology**: Used in the first FDA-approved gene therapy for sickle cell disease, showcasing advancements in hematopathology. - **CTO-H**: A comprehensive database launched by ConcertAI and NeoGenomics to improve clinical trial designs for hematological malignancies. - **Advanced Biomedical Testing**: Beckman Coulter's diagnostic systems are utilized globally to enhance healthcare outcomes through innovative solutions in hematology and urinalysis. - **Tapestri Platform**: Developed by Mission Bio, this platform is advancing research in blood cancers through single-cell multiomics. - **Hematology and Oncology Research**: Incyte Corporation invests significantly in R&D to drive innovation in hematology and oncology therapeutics. - **Cell Therapy Monitoring**: The use of CareDx's AlloCell test to monitor the expansion and persistence of TCB008, an allogeneic gamma-delta T-cell therapy, in patients with blood cancers. - **AI in Pathology**: AI technologies are being developed to assist pathologists in detecting and grading tumors, improving diagnostic accuracy. - **Enterprise Imaging for Pathology**: AGFA HealthCare launched a platform to enhance workflow and efficiency in pathology departments. - **CAR T-cell Therapy Market Growth**: Significant growth driven by increasing product approvals and clinical trials, particularly for hematologic malignancies. - **Gene Editing Therapies**: Emerging therapies like BEAM-101 utilizing base-editing technology for sickle cell disease. - **Precision Oncology**: Guardant Health focuses on improving patient outcomes through advanced diagnostics and AI analytics. - **High-Fiber Diet**: Studies suggest it can improve gut microbiome health, potentially reducing complications in blood disorder patients. - **Precision Medicine**: Caris Life Sciences is advancing precision oncology, focusing on biomarker-driven research to improve cancer treatment outcomes. - **Biosimulation Technology**: Cellworks' platform predicts treatment outcomes for cancer patients, showcasing advancements in personalized medicine. ### Challenges and Concerns - **Shortage of Pathologists**: The growing demand for pathology services amid a shortage of qualified professionals, necessitating innovative solutions. - **Market Competition**: The increasing competition in the hematology oncology space, particularly with the rise of personalized medicine and targeted therapies. - **Regulatory Hurdles**: Biopharmaceutical companies face challenges in navigating the regulatory landscape for new hematology therapies. - **Model Interpretability**: Challenges in understanding AI model decisions in digital pathology. - **High Costs of CAR T-cell Therapies**: Despite advancements, the high costs and systemic toxicity of CAR T-cell therapies remain a concern. - **Market Viability**: Concerns about the viability of cell therapies for autoimmune conditions have arisen, particularly following significant stock declines. - **High Therapy Costs**: The CAR T-cell therapy market faces challenges due to high therapy costs and potential adverse effects. - **Safety Risks in Trials**: The death of a patient in the BEAM-101 trial highlights the risks associated with preconditioning treatments. - **Regulatory Compliance**: Clinical laboratories must achieve compliance with the FDA's LDT rule by May 2025, necessitating immediate action to protect valuable LDTs. - **Medical Mistrust**: Addressing medical mistrust in underrepresented communities is crucial for improving cancer care and patient transitions. - **Data Privacy**: Concerns regarding the handling of personal data in healthcare applications, emphasizing the importance of user consent and data protection. - **Dataset Biases**: Concerns regarding biases in datasets used for training AI models, affecting diagnostic accuracy. - **Health Inequities**: Issues related to equitable access to AI-driven healthcare solutions, particularly in low-income countries. - **Data Privacy and Algorithmic Bias**: Ethical and legal concerns surrounding AI in healthcare, including the need for transparency and training for healthcare providers. - **Adoption of Biosimilars**: Despite their potential, physician preference for original biologics and legislative restrictions hinder the widespread use of biosimilars. - **Tobacco Exposure**: Evidence highlights its negative impact on cancer development, emphasizing the need for smoking cessation. - **Data Interoperability Issues**: The need for data interoperability and human oversight in clinical decision-making poses challenges for AI integration. - **Regulatory Hurdles for AI**: Challenges regarding reimbursement models and regulatory restrictions hinder broader deployment of AI in healthcare. ## Related Topics [[Hematology]]